The effect of cold ischemia time and/or formalin fixation on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 results in breast carcinoma

Pathology Research International

Volumn 2012, Issue , 2012, Pages

  Pekmezci, Melike ^a   Szpaderska, Anna ^a   Osipo, Clodia ^a   Erşahin, Çaatay ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866246317     PISSN: None     EISSN: 2042003X     Source Type: Journal    
DOI: 10.1155/2012/947041     Document Type: Article

References (29)

1. Viale G., Regan M. M., Maiorano E., Mastropasqua M. G., Dell'Orto P., Rasmussen B. B., Raffoul J., Neven P., Orosz Z., Braye S., Öhlschlegel C., Thürlimann B., Gelber R. D., Castiglione-Gertsch M., Price K. N., Goldhirsch A., Gusterson B. A., Coates A. S., Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 198. Journal of Clinical Oncology 2007 25 25 3846 3852 2-s2.0-34548536058 10.1200/JCO.2007.11.9453 (Pubitemid 47477259)
2. Allred D. C., Harvey J. M., Berardo M., Clark G. M., Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 1998 11 2 155 168 2-s2.0-0031915998 (Pubitemid 28144151)
3. Mohsin S. K., Weiss H., Havighurst T., Clark G. M., Berardo M., Roanh L. D., To T. V., Zho Q., Love R. R., Allred D. C., Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Modern Pathology 2004 17 12 1545 1554 2-s2.0-10344263365 10.1038/modpathol. 3800229 (Pubitemid 39627082)
4. Stendahl M., Rydén L., Nordenskjöld B., Jönsson P. E., Landberg G., Jirström K., karin.jirstrom@med.lu.se High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clinical Cancer Research 2006 12 15 4614 4618 10.1158/1078-0432.CCR-06-0248 (Pubitemid 44297812)
5. Abe O., Abe R., Enomoto K., Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet 1998 351 9114 1451 1467 10.1016/S0140-6736(97)11423-4 (Pubitemid 28227036)
6. Paik S., Hazan R., Fisher E. R., Sass R. E., Fisher B., Redmond C., Schlessinger J., Lippman M. E., King C. R., Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology 1990 8 1 103 112 2-s2.0-0025177290 (Pubitemid 20032452)
7. Press M. F., Bernstein L., Thomas P. A., Meisner L. F., Zhou J. Y., Ma Y., Hung G., Robinson R. A., Harris C., El-Naggar A., Slamon D. J., Phillips R. N., Ross J. S., Wolman S. R., Flom K. J., HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology 1997 15 8 2894 2904 2-s2.0-18244422222 (Pubitemid 27330017)
8. De Laurentiis M., Arpino G., Massarelli E., Ruggiero A., Carlomagno C., Ciardiello F., Tortora G., D'Agostino D., Caputo F., Cancello G., Montagna E., Malorni L., Zinno L., Lauria R., Bianco A. R., De Placido S., A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clinical Cancer Research 2005 11 13 4741 4748 2-s2.0-27644597480 10.1158/1078-0432.CCR-04-2569 (Pubitemid 41557193)
9. Vogel C. L., Cobleigh M. A., Tripathy D., Gutheil J. C., Harris L. N., Fehrenbacher L., Slamon D. J., Murphy M., Novotny W. F., Burchmore M., Shak S., Stewart S. J., Press M., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 2002 20 3 719 726 2-s2.0-0036467826 10.1200/JCO.20.3.719 (Pubitemid 34111379)
10. Wolff A. C., Hammond M. E. H., Schwartz J. N., Hagerty K. L., Alfred D. C., Cote R. J., Dowsett M., Fitzgibbons P. L., Hanna W. M., Langer A., McShane L. M., Paik S., Pegram M. D., Perez E. A., Press M. F., Rhodes A., Sturgeon C., Taube S. E., Tubbs R., Vance G. H., Van De Vijver M., Wheeler T. M., Hayes D. F., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of Pathology and Laboratory Medicine 2007 131 1 18 43 2-s2.0-33846568336 (Pubitemid 46174133)
11. Hammond M. E. H., Hayes D. F., Dowsett M., Allred D. C., Hagerty K. L., Badve S., Fitzgibbons P. L., Francis G., Goldstein N. S., Hayes M., Hicks D. G., Lester S., Love R., Mangu P. B., McShane L., Miller K., Osborne C. K., Paik S., Perlmutter J., Rhodes A., Sasano H., Schwartz J. N., Sweep F. C. G., Taube S., Torlakovic E. E., Valenstein P., Viale G., Visscher D., Wheeler T., Williams R. B., Wittliff J. L., Wolff A. C., American Society of Clinical oncology/college of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Archives of Pathology and Laboratory Medicine 2010 134 6 907 922 2-s2.0-77953198056
12. Uy G., Laudico A., Carnate J. Jr., Lim F., Fernandez A., Rivera R., Mapua C., Love R., Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients. Clinical Breast Cancer 2010 10 2 154 159 2-s2.0-77950482080 10.3816/CBC.2010.n.021
13. Mann G. B., Fahey V. D., Feleppa F., Buchanan M. R., Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. Journal of Clinical Oncology 2005 23 22 5148 5154 2-s2.0-24644448364 10.1200/JCO.2005.02.076 (Pubitemid 46224023)
14. Young S. C., Burkett R. J., Stewart C., Discrepancy in ER levels of breast carcinoma in biopsy vs mastectomy specimens. Journal of Surgical Oncology 1985 29 1 54 56 2-s2.0-0021827844 (Pubitemid 15032899)
15. Teicher I., Tinker M. A., Auguste L. J., Effect of operative devascularization on estrogen and progesterone receptor levels in breast cancer specimens. Surgery 1985 98 4 784 791 2-s2.0-0022396277 (Pubitemid 16164139)
16. Meyer J. S., Schechtman K., Valdes R. Jr., Estrogen and progesterone receptor assays on breast carcinoma from mastectomy specimens. Cancer 1983 52 11 2139 2143 2-s2.0-0021075995 (Pubitemid 14232259)
17. Hasson J., Luhan P. A., Kohl M. W., Comparison of estrogen receptor levels in breast cancer samples from mastectomy and frozen section specimens. Cancer 1981 47 1 138 139 2-s2.0-0019363463 (Pubitemid 11167372)
18. Ellis L. M., Wittliff J. L., Bryant M. S., Sitren H. S., Hogancamp W. E., Souba W. W., Bland K. I., Lability of steroid hormone receptors following devascularization of breast tumors. Archives of Surgery 1989 124 1 39 42 2-s2.0-0024540961 (Pubitemid 19025901)
19. Goldstein N. S., Ferkowicz M., Odish E., Mani A., Hastah F., Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. American Journal of Clinical Pathology 2003 120 1 86 92 2-s2.0-0038447978 10.1309/QPHD-RB00-QXGM-UQ9N (Pubitemid 37046374)
20. Khoury T., Sait S., Hwang H., Chandrasekhar R., Wilding G., Tan D., Kulkarni S., Delay to formalin fixation effect on breast biomarkers. Modern Pathology 2009 22 11 1457 1467 2-s2.0-70350680445 10.1038/modpathol.2009.117
21. Qiu J., Kulkarni S., Chandrasekhar R., Rees M., Hyde K., Wilding G., Tan D., Khoury T., Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones. American Journal of Clinical Pathology 2010 134 5 813 819 2-s2.0-78049514308 10.1309/ AJCPVCX83JWMSBNO
22. Bhargava R., Esposito N. N., Dabbs D. J., Dabbs D. J., Immunohistology of the breast. Diagnostic Immunohistochemistry Theranostic and Genomic Applications 2010 3rd Philadelphia, Pa, USA Elsevier Saunders 763 819
23. Apple S., Pucci R., Lowe A. C., Shintaku I., Shapourifar-Tehrani S., Moatamed N., The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma. American Journal of Clinical Pathology 2011 135 4 592 598 10.1309/ AJCPB1RIT5YXMRIS
24. Lowe A. C., Nanjangud G., Shintaku I., Effect of ischemic time, fixation time and fixatives on Her-2/Neu IHC and FISH results in breast cancer. Modern Pathology 2011 24 supplement 1, 59A-Abstract 206
25. Portier B., Downs-Kelly E., Rowe J., Cold ischemia time: effect on HER2 detection by In-Situ hybridization and immunohistochemistry. Modern Pathology 2011 24 supplement 1, 52A-Abstract 206. Abstract No. 236
26. Jacobs T. W., Prioleau J. E., Stillman I. E., Schnitt S. J., Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. Journal of the National Cancer Institute 1996 88 15 1054 1059 2-s2.0-0029742823 (Pubitemid 26260491)
27. Mirlacher M., Kasper M., Storz M., Knecht Y., Dürmüller U., Simon R., Mihatsch M. J., Sauter G., Influence of slide aging on results of translational research studies using immunohistochemistry. Modern Pathology 2004 17 11 1414 1420 2-s2.0-8144222903 10.1038/modpathol.3800208 (Pubitemid 39472998)
28. Barnes D. M., Millis R. R., Beex L. V. A. M., Thorpe S. M., Leake R. E., Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. European Journal of Cancer 1998 34 11 1677 1682 2-s2.0-0032190388 10.1016/S0959-8049(98)00149-X (Pubitemid 28474218)
29. Paik S., Kim C., Wolmark N., HER2 status and benefit from adjuvant trastuzumab in breast cancer. The New England Journal of Medicine 2008 358 13 1409 1411 2-s2.0-41449105551 10.1056/NEJMc0801440 (Pubitemid 351468442)